Formulating cannabinoids for the oral route of administration
Enhancing oral bioavailability of cannabinoids with lipid-based formulations
Lipid-based formulations solubilize and maintain the drug in solubilized state throughout the gastro-intestinal tract, leading to normalized drug absorption and increased bioavailability. Reduction of food effect, increase in lymphatic transport or increase in intestinal permeation are recorded depending on the components of the formulation.
Different types of formulations can be prepared from simple oily formulation to self-emulsifying drug delivery systems depending on the final dosage forms (tinctures, drops, capsules…).
Watch our video to know more about lipid-based formulation development
Our solutions for oral delivery of cannabinoids at a glance
| Dosage form |
Tinctures |
Soft caps |
Hard caps |
Hard caps Solid filled |
Tablets |
|---|---|---|---|---|---|
| Excipient Function | |||||
| Solubilizer | |||||
| Intestinal permeation enhancer | |||||
| Promoter of lymphatic absorption | |||||
| Sustained release agent | |||||
| Lubricant | Precirol® ATO 5 | Compritol® 888 ATO | |||
Tinctures or oily solutions
Recommended oil: Maisine® CC
- Increases oral bioavailability, due to solubilization and lymphatic transport
- Contains natural antioxidant
- Nice taste, like corn oil
Recommended self-emulsifying excipient: Labrafil® M 1944 CS
- Increases oral bioavailability, due to solubilization and lymphatic transport
- Contains natural antioxidant
- Instantaneous dispersion in water, when predilution is desired
Self emulsifiying drug delivery systems (SEDDS)
Use one of our SEDDS proposal:
- Gelucire® 44/14:Lauroglycol™ 90:Maisine® CC (70:10:20)
- Labrasol® ALF:Plurol® Oleique CC 497:Labrafil® M 1944 CS (70:10:20) or (10:10:80)
- Gelucire® 44/14:Capryol® 90:Labrafil® M 1944 CS (50:30:20)
Or develop you own SEDDS formulation following our protocol!